Company / Operating Income
TScan Therapeutics, Inc. Operating Income History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$134.8M
FY2025
5-year range
-$134.8M / -$26.2M
FY2021-FY2025
Trend
-44.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has declined for 4 consecutive years, from -$26M in FY2021 to -$135M in FY2025.
Based on SEC 10-K filings.
-$135M in FY2025.
Declined from -$67M to -$135M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- TScan Therapeutics, Inc.'s operating income has declined for 4 consecutive years.
- In FY2025, operating income decreased 44.3% year-over-year.
- Peak operating income was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -9.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$134.8M | -44.3% |
| FY2024 | -$93.5M | -40.3% |
| FY2023 | -$66.6M | -37.0% |
| FY2022 | -$48.6M | -85.4% |
| FY2021 | -$26.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026